UNSPSC 51184015: Tolazamide

This classification denotes an anti-diabetic agent with the molecular formula C14H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9LT1BRO48Q, chemically known as 4-(p-tolylsulfonyl)-1,1-hexamethylenesemicarbazide but more generally known as tolazamide, which bears US NIH Compound Identifier 5503. European Medicines Agency schedules Tolazamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11147MIG.

UNSPSC 51184015 Tolazamide, a Commodity code, encompasses generic pharmaceutical products supplied through state and local cooperative purchasing agreements to healthcare facilities and government agencies. State and local governments procure tolazamide and related generic pharmaceuticals through multi-state cooperative purchasing vehicles that consolidate demand across participating jurisdictions, reducing per-unit costs and simplifying vendor management for healthcare operations, correctional facilities, and other public health programs. Issuing bodies under this code include state health departments and purchasing offices that administer cooperative agreements on behalf of multiple member states and their subordinate agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary vehicle for this activity, consolidating purchasing power across participating states including Oregon alongside Minnesota's own state and local facilities.

MMCAP issued a Request for Proposal (RFP S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Awarded vendors will be provided to wholesalers by May 15, 2026, with contracts effective July 1, 2026 for an initial two-year term. Evaluation weights pricing competitiveness (75 percent), fixed pricing (10 percent), and EDI capability, compliance with administrative fee formatting, and acceptance of a 3 percent administrative fee (5 percent each). Vendors must maintain commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, and accept performance penalties ranging from $200 to $1,500 per violation. No specific set-aside designations are noted in the available documentation, and no award value or budget range is disclosed.